Daisuke Watanabe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Daisuke Watanabe has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Satoshi Morimoto
Department of Medicine, Tokyo Women’s Medical University Adachi Medical Center, Tokyo, Japan
15 shared publications - Yasufumi Seki
Division of Hormonal Medicine and Bioregulatory Science, Department of Medicine, Tokyo Women's Medical University, Tokyo, Japan
12 shared publications Atsuhiro Ichihara
Department of Endocrinology and Hypertension, Tokyo Women’s Medical University 2
10 shared publications- Atsuhiro Ichihara
Department of Endocrinology and Hypertension, Tokyo Women’s Medical University, Tokyo, Japan
9 shared publications - Midori Yatabe
Department of Medicine II, Endocrinology and Hypertension, Tokyo Women's Medical University, Tokyo, Japan
8 shared publications - Junichi Yatabe
General Incorporated Association TelemedEASE, Tokyo, Japan
7 shared publications
Latest Publications
- Open Access
- 31 July 2026
- Published by Bioscientifica in Endocrine Connections
- Vol. 15 (8)
Inhibitory mechanism of ANP on aldosterone production in human adrenocortical cells
Objective: The aldosterone-suppressing effect of natriuretic peptides (NPs) has been demonstrated in experiments using adrenocortical cells from various animal species. 3′,5′-cyclic guanosine monophosphate (cGMP), which is produced by atrial natriuretic peptide (ANP), is recognized as a suppressor of aldosterone production. However, it has also been reported that cGMP does not exhibit the same aldosterone-suppressing effect as ANP. Therefore, we examined the effect of ANP on aldosterone suppression using various inhibitors and agonists, including a cGMP agonist. Design: We investigated the expression of ANP receptors in human adrenocortical cells. Next, we examined aldosterone synthesis gene expressions and the effects of various inhibitors, agonists, and siRNAs for the two ANP receptors on the aldosterone-suppressing action of ANP using human adrenocortical H295R cells, precultured with Ang-II. We also investigated inhibitory G (Gi) protein signaling as a cGMP-independent factor. Results: The human adrenocortical cell line H295R was shown to express the guanylyl cyclase A receptor (NPR1). Treatment with a neprilysin inhibitor ameliorated ANP-induced suppression of aldosterone production. Aldosterone production elevated by cyclic adenosine monophosphate (cAMP) agonist was significantly reduced by inhibitors of cAMP signaling. Conversely, cGMP alone had no significant aldosterone-suppressing effect. By suppressing the expression of receptors NPR1 and guanylyl cyclase C receptor (NPR3), aldosterone production increased in the presence of ANP. The suppression of aldosterone production by ANP was abolished by blocking Gi signaling by pertussis toxin (PTX). Conclusion: These results suggest that ANP suppresses aldosterone production in H295R cells through NPR1 and NPR3, and this suppression is partially mediated by a cGMP-independent Gi signaling.
- 31 July 2026
- Published by Bioscientifica in Endocrine Connections
- Vol. 15 (8)
Open AccessInhibitory mechanism of ANP on aldosterone production in human adrenocortical cells
Objective: The aldosterone-suppressing effect of natriuretic peptides (NPs) has been demonstrated in experiments using adrenocortical cells from various animal species. 3′,5′-cyclic guanosine monophosphate (cGMP), which is produced by atrial natriuretic peptide (ANP), is recognized as a suppressor of aldosterone production. However, it has also been reported that cGMP does not exhibit the same aldosterone-suppressing effect as ANP. Therefore, we examined the effect of ANP on aldosterone suppression using various inhibitors and agonists, including a cGMP agonist. Design: We investigated the expression of ANP receptors in human adrenocortical cells. Next, we examined aldosterone synthesis gene expressions and the effects of various inhibitors, agonists, and siRNAs for the two ANP receptors on the aldosterone-suppressing action of ANP using human adrenocortical H295R cells, precultured with Ang-II. We also investigated inhibitory G (Gi) protein signaling as a cGMP-independent factor. Results: The human adrenocortical cell line H295R was shown to express the guanylyl cyclase A receptor (NPR1). Treatment with a neprilysin inhibitor ameliorated ANP-induced suppression of aldosterone production. Aldosterone production elevated by cyclic adenosine monophosphate (cAMP) agonist was significantly reduced by inhibitors of cAMP signaling. Conversely, cGMP alone had no significant aldosterone-suppressing effect. By suppressing the expression of receptors NPR1 and guanylyl cyclase C receptor (NPR3), aldosterone production increased in the presence of ANP. The suppression of aldosterone production by ANP was abolished by blocking Gi signaling by pertussis toxin (PTX). Conclusion: These results suggest that ANP suppresses aldosterone production in H295R cells through NPR1 and NPR3, and this suppression is partially mediated by a cGMP-independent Gi signaling.
- Open Access
- 16 July 2026
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 49 (11) , 3353-3363
Association between adipose (pro)renin receptor expression and growth hormone deficiency in patients with non-functioning hypothalamic-pituitary masses
Purpose Fat accumulation leads to obesity, which increases the risk of cardiovascular diseases. Recent studies have shown that adipose (pro)renin receptor ([P]RR) may play a role in fat accumulation, and we previously reported increased adipose (P)RR expression in growth hormone (GH) deficiency in mice; however, the association between human adipose (P)RR expression and GH deficiency remains unclear. Methods In this prospective study, abdominal subcutaneous adipose tissue was collected during pituitary surgery in patients with non-functioning hypothalamic-pituitary masses, and the associations between adipose (P)RR mRNA expression, determined using reverse transcription-polymerase chain reaction, and GH deficiency and other clinical parameters were investigated. Results Fifteen patients (5 craniopharyngioma, 4 non-functioning pituitary neuroendocrine tumor, 4 Rathke’s cleft cyst, and 2 other diseases) (mean age, 53 ± 17 years; male sex, 3 [20%]; and mean body mass index [BMI], 24.8 ± 4.3 kg/m2; GH deficiency, 8 [53%]) were included. Adipose (P)RR mRNA expression was significantly higher in patients with GH deficiency (P = 0.009) compared to those without, but was not significantly associated with other pituitary functions. Adipose (P)RR mRNA expression was significantly correlated with BMI (r = 0.526, P = 0.044) and body fat mass (r = 0.728, P = 0.026, n = 9). GH deficiency was significantly associated with (P)RR mRNA after adjustment for obesity (β = 2.257, 95% CI: 0.367–4.417, P = 0.023). Conclusion Adipose (P)RR expression may be increased in GH deficiency, suggesting the possible role of adipose (P)RR in fat accumulation in GH deficiency.
- 16 July 2026
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 49 (11) , 3353-3363
Open AccessAssociation between adipose (pro)renin receptor expression and growth hormone deficiency in patients with non-functioning hypothalamic-pituitary masses
Purpose Fat accumulation leads to obesity, which increases the risk of cardiovascular diseases. Recent studies have shown that adipose (pro)renin receptor ([P]RR) may play a role in fat accumulation, and we previously reported increased adipose (P)RR expression in growth hormone (GH) deficiency in mice; however, the association between human adipose (P)RR expression and GH deficiency remains unclear. Methods In this prospective study, abdominal subcutaneous adipose tissue was collected during pituitary surgery in patients with non-functioning hypothalamic-pituitary masses, and the associations between adipose (P)RR mRNA expression, determined using reverse transcription-polymerase chain reaction, and GH deficiency and other clinical parameters were investigated. Results Fifteen patients (5 craniopharyngioma, 4 non-functioning pituitary neuroendocrine tumor, 4 Rathke’s cleft cyst, and 2 other diseases) (mean age, 53 ± 17 years; male sex, 3 [20%]; and mean body mass index [BMI], 24.8 ± 4.3 kg/m2; GH deficiency, 8 [53%]) were included. Adipose (P)RR mRNA expression was significantly higher in patients with GH deficiency (P = 0.009) compared to those without, but was not significantly associated with other pituitary functions. Adipose (P)RR mRNA expression was significantly correlated with BMI (r = 0.526, P = 0.044) and body fat mass (r = 0.728, P = 0.026, n = 9). GH deficiency was significantly associated with (P)RR mRNA after adjustment for obesity (β = 2.257, 95% CI: 0.367–4.417, P = 0.023). Conclusion Adipose (P)RR expression may be increased in GH deficiency, suggesting the possible role of adipose (P)RR in fat accumulation in GH deficiency.
- Open Access
- 21 April 2026
- Published by The Endocrine Society in JCEM Case Reports
- Vol. 4 (5) , luag053
Drug-induced liver injury due to potassium iodide during thyroid storm
Thyroid storm is a life-threatening condition causing multiorgan failure, including liver dysfunction. Potassium iodide (KI) is one of the key drugs used to control thyroid hormone levels. While thionamides sometimes cause drug-induced liver injury (DILI), KI has not been reported to cause DILI. Herein, we report a case of likely KI-induced DILI during treatment for thyroid storm due to Graves disease. A 30-year-old man presented with thyrotoxicosis due to Graves disease, with hyperbilirubinemia and elevated liver transaminases. The patient was diagnosed with thyroid storm, and treatment was initiated with methimazole, KI, corticosteroids, and beta-blockers. Although the thyroid hormone levels improved during the treatment, total bilirubin levels increased to 32.4 mg/dL (SI: 553 µmol/L) (reference range, <1.2 mg/dL [SI: <20.5 µmol/L]). DILI was suspected, and methimazole was discontinued; however, bilirubin levels remained elevated. Plasma exchange also failed to improve the liver injury. After KI was discontinued, the bilirubin levels rapidly decreased. Lymphocyte transformation tests for methimazole and KI were negative and positive, respectively, confirming the diagnosis of KI-induced DILI. This case highlights that KI should be recognized as a potential cause of DILI in patients with KI therapy who present with abnormal liver function.
- 21 April 2026
- Published by The Endocrine Society in JCEM Case Reports
- Vol. 4 (5) , luag053
Open AccessDrug-induced liver injury due to potassium iodide during thyroid storm
Thyroid storm is a life-threatening condition causing multiorgan failure, including liver dysfunction. Potassium iodide (KI) is one of the key drugs used to control thyroid hormone levels. While thionamides sometimes cause drug-induced liver injury (DILI), KI has not been reported to cause DILI. Herein, we report a case of likely KI-induced DILI during treatment for thyroid storm due to Graves disease. A 30-year-old man presented with thyrotoxicosis due to Graves disease, with hyperbilirubinemia and elevated liver transaminases. The patient was diagnosed with thyroid storm, and treatment was initiated with methimazole, KI, corticosteroids, and beta-blockers. Although the thyroid hormone levels improved during the treatment, total bilirubin levels increased to 32.4 mg/dL (SI: 553 µmol/L) (reference range, <1.2 mg/dL [SI: <20.5 µmol/L]). DILI was suspected, and methimazole was discontinued; however, bilirubin levels remained elevated. Plasma exchange also failed to improve the liver injury. After KI was discontinued, the bilirubin levels rapidly decreased. Lymphocyte transformation tests for methimazole and KI were negative and positive, respectively, confirming the diagnosis of KI-induced DILI. This case highlights that KI should be recognized as a potential cause of DILI in patients with KI therapy who present with abnormal liver function.
- 29 July 2025
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 48 (11) , 2633-2641
Reduced high-sensitivity C-reactive protein levels following weekly somapacitan in adults with growth hormone deficiency: a prospective pilot study
Growth hormone (GH) deficiency (GHD) elevates high-sensitivity C-reactive protein (hs-CRP) levels, an inflammatory marker. While daily GH replacement has been shown to reduce hs-CRP levels, the effects of long-acting GH therapyon hs-CRP remain unclear. This pilot study aimed to investigate the association between a once-weekly GH derivative, somapacitan, and hs-CRP in adult patients with GHD. This study prospectively evaluated serum hs-CRP levels and metabolic parameters in adult patients with untreated GHD during a 6-month course of weekly somapacitan therapy. Among 13 adult patients with GHD (9 men; 10 with adult-onset GHD), serum hs-CRP levels significantly decreased following somapacitan therapy (0.24 [0.07-0.51] to 0.07 [0.06-0.25] mg/dL, P <.001), whereas serum insulin-like growth factor (IGF)-1 levels (80 ± 53 to 148 ± 74 ng/mL, P <.001) and IGF-1 SD scores (- 2.8 ± 2.3 to - 0.4 ± 1.7, P <.001) significantly increased. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels showed slight but statistically insignificant decreases after the treatment. Changes in hs-CRP levels correlated significantly with changes in IGF-1 SD scores (r = -.66, P =.01), AST (r =.67, P =.01), and ALT (r =.74, P =.004). In partial correlation analyses, changes in hs-CRP levels remained significantly associated with ALT changes (r =.59, P =.04), independent of IGF-1 SD score changes. The reduction in hs-CRP levels after somapacitan therapy for GHD suggests that somapacitan has a protective role against inflammation, possibly mediated by the liver.
- 29 July 2025
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 48 (11) , 2633-2641
Reduced high-sensitivity C-reactive protein levels following weekly somapacitan in adults with growth hormone deficiency: a prospective pilot study
Growth hormone (GH) deficiency (GHD) elevates high-sensitivity C-reactive protein (hs-CRP) levels, an inflammatory marker. While daily GH replacement has been shown to reduce hs-CRP levels, the effects of long-acting GH therapyon hs-CRP remain unclear. This pilot study aimed to investigate the association between a once-weekly GH derivative, somapacitan, and hs-CRP in adult patients with GHD. This study prospectively evaluated serum hs-CRP levels and metabolic parameters in adult patients with untreated GHD during a 6-month course of weekly somapacitan therapy. Among 13 adult patients with GHD (9 men; 10 with adult-onset GHD), serum hs-CRP levels significantly decreased following somapacitan therapy (0.24 [0.07-0.51] to 0.07 [0.06-0.25] mg/dL, P <.001), whereas serum insulin-like growth factor (IGF)-1 levels (80 ± 53 to 148 ± 74 ng/mL, P <.001) and IGF-1 SD scores (- 2.8 ± 2.3 to - 0.4 ± 1.7, P <.001) significantly increased. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels showed slight but statistically insignificant decreases after the treatment. Changes in hs-CRP levels correlated significantly with changes in IGF-1 SD scores (r = -.66, P =.01), AST (r =.67, P =.01), and ALT (r =.74, P =.004). In partial correlation analyses, changes in hs-CRP levels remained significantly associated with ALT changes (r =.59, P =.04), independent of IGF-1 SD score changes. The reduction in hs-CRP levels after somapacitan therapy for GHD suggests that somapacitan has a protective role against inflammation, possibly mediated by the liver.
- Open Access
- 17 July 2025
- Published by The Endocrine Society in JCEM Case Reports
- Vol. 3 (9) , luaf173
A Rare Coexistence of Thyrotropin-Secreting Pituitary Adenoma and Graves Disease
The coexistence of Graves disease (GD) and a thyroid-stimulating hormone (TSH)–secreting pituitary adenoma (TSHoma) is a rare and diagnostically challenging condition. In general, GD typically manifests with low TSH because of excess thyroid hormone production; contrastingly, a TSHoma causes secondary hyperthyroidism with normal or elevated TSH levels. This unusual overlap poses diagnostic and therapeutic challenges; therefore, a careful approach is required to distinguish and manage both conditions. We present the case of a 51-year-old woman with symptoms of hyperthyroidism, elevated thyroid hormones, low TSH, and positive anti-TSH receptor antibodies, which were suggestive of GD 10 years prior. After stopping thiamazole and levothyroxine because of the favorable control of thyroid function 6 months prior, the patient presented a syndrome of inappropriate secretion of TSH and magnetic resonance imaging revealed a pituitary macroadenoma; accordingly, she was diagnosed with concurrent GD and a TSHoma. Treatment involved transsphenoidal resection of the TSHoma and antithyroid medication to control GD. This case illustrates the rarity of coexisting GD and TSHoma and the diagnostic and therapeutic complexities of managing dual hyperthyroidism etiologies. Biochemical testing, antibody assessment, and imaging examination are essential for accurate and early diagnosis of the condition.
- 17 July 2025
- Published by The Endocrine Society in JCEM Case Reports
- Vol. 3 (9) , luaf173
Open AccessA Rare Coexistence of Thyrotropin-Secreting Pituitary Adenoma and Graves Disease
The coexistence of Graves disease (GD) and a thyroid-stimulating hormone (TSH)–secreting pituitary adenoma (TSHoma) is a rare and diagnostically challenging condition. In general, GD typically manifests with low TSH because of excess thyroid hormone production; contrastingly, a TSHoma causes secondary hyperthyroidism with normal or elevated TSH levels. This unusual overlap poses diagnostic and therapeutic challenges; therefore, a careful approach is required to distinguish and manage both conditions. We present the case of a 51-year-old woman with symptoms of hyperthyroidism, elevated thyroid hormones, low TSH, and positive anti-TSH receptor antibodies, which were suggestive of GD 10 years prior. After stopping thiamazole and levothyroxine because of the favorable control of thyroid function 6 months prior, the patient presented a syndrome of inappropriate secretion of TSH and magnetic resonance imaging revealed a pituitary macroadenoma; accordingly, she was diagnosed with concurrent GD and a TSHoma. Treatment involved transsphenoidal resection of the TSHoma and antithyroid medication to control GD. This case illustrates the rarity of coexisting GD and TSHoma and the diagnostic and therapeutic complexities of managing dual hyperthyroidism etiologies. Biochemical testing, antibody assessment, and imaging examination are essential for accurate and early diagnosis of the condition.
- Open Access
- 2 November 2023
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 7 (12) , bvad137
Effect of GH Deficiency Caused by Nonfunctioning Pituitary Masses on Serum C-reactive Protein Levels
Context GH supplementation for GH deficiency (GHD) has been reported to decrease high-sensitivity C-reactive protein (hs-CRP), an inflammatory marker; however, the association between GHD and hs-CRP remains unclear. Objective We aimed to clarify the impact of impaired GH secretion due to pituitary masses on hs-CRP levels. Methods We retrospectively examined the association between GH secretion, assessed using GH-releasing peptide-2, and serum hs-CRP levels before and a year after the pituitary surgery in patients with nonfunctioning pituitary neuroendocrine tumor or Rathke cleft cyst. Results Among 171 patients, 55 (32%) presented with severe GHD (peak GH response to GH-releasing peptide-2 < 9 ng/mL). Serum hs-CRP levels were significantly higher in patients with severe GHD than in those without (P < .001) and significantly correlated with the peak GH (r = −0.50, P < .001). Multiple regression analyses showed that the peak GH significantly and negatively predicted hs-CRP levels (β = −0.345; 95% CI, −0.533 to −0.158) and the lowest quartile of the peak GH (<5.04 ng/mL) were significantly associated with increase in hs-CRP levels (exp [β] = 1.840; 95% CI, 1.209 to 2.801), after controlling for other anterior hormones and metabolic parameters. Postoperative change in the peak GH (N = 60) significantly predicted change in hs-CRP levels (β = −0.391; 95% CI, −0.675 to −0.108), independent of alterations in other anterior hormones and metabolic parameters. Conclusion The inverse association between GH secretion and hs-CRP levels highlights the protective role of GH in the increase in hs-CRP.
- 2 November 2023
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 7 (12) , bvad137
Open AccessEffect of GH Deficiency Caused by Nonfunctioning Pituitary Masses on Serum C-reactive Protein Levels
Context GH supplementation for GH deficiency (GHD) has been reported to decrease high-sensitivity C-reactive protein (hs-CRP), an inflammatory marker; however, the association between GHD and hs-CRP remains unclear. Objective We aimed to clarify the impact of impaired GH secretion due to pituitary masses on hs-CRP levels. Methods We retrospectively examined the association between GH secretion, assessed using GH-releasing peptide-2, and serum hs-CRP levels before and a year after the pituitary surgery in patients with nonfunctioning pituitary neuroendocrine tumor or Rathke cleft cyst. Results Among 171 patients, 55 (32%) presented with severe GHD (peak GH response to GH-releasing peptide-2 < 9 ng/mL). Serum hs-CRP levels were significantly higher in patients with severe GHD than in those without (P < .001) and significantly correlated with the peak GH (r = −0.50, P < .001). Multiple regression analyses showed that the peak GH significantly and negatively predicted hs-CRP levels (β = −0.345; 95% CI, −0.533 to −0.158) and the lowest quartile of the peak GH (<5.04 ng/mL) were significantly associated with increase in hs-CRP levels (exp [β] = 1.840; 95% CI, 1.209 to 2.801), after controlling for other anterior hormones and metabolic parameters. Postoperative change in the peak GH (N = 60) significantly predicted change in hs-CRP levels (β = −0.391; 95% CI, −0.675 to −0.108), independent of alterations in other anterior hormones and metabolic parameters. Conclusion The inverse association between GH secretion and hs-CRP levels highlights the protective role of GH in the increase in hs-CRP.
- Open Access
- 20 October 2023
- Published by S. Karger AG in Kidney and Blood Pressure Research
- Vol. 48 (1) , 688-700
Effects of Aliskiren Monotherapy versus Amlodipine Monotherapy in Hypertensive Patients with Obesity or Type 2 Diabetes Mellitus
Introduction: Renin-angiotensin system inhibitors have been reported to exert protective effects against organ damage and failure; however, the impact of the direct renin inhibitor as monotherapy has not been assessed. Here, we investigated the effects of 24-week monotherapy with aliskiren compared to amlodipine in hypertensive patients with type 2 diabetes or obesity. Methods: In this randomized intervention study, 62 adult hypertensive patients with visceral obesity (defined as a body mass index [BMI] greater than 25 kg/m2 and a visceral adipose tissue area [VFA] greater than 100 cm2) or type 2 diabetes mellitus (age 57 ± 13, 65% men, BMI 28.8 ± 4.8 kg/m2, VFA 134.8 ± 47.0 cm2, blood pressure 141 ± 16/86 ± 13 mm Hg) were randomized to receive 24-week treatment with aliskiren (max. 300 mg) or amlodipine (max. 10 mg). The primary outcome was the change in VFA at 24 weeks post-treatment. Results: Change in VFA did not differ significantly from baseline in either group. Systolic blood pressure significantly decreased at 12 weeks (−10 mm Hg, p = 0.001) and 24 weeks (−10 mm Hg, p = 0.001) in the amlodipine group and at 24 weeks (−11 mm Hg, p = 0.001) in the aliskiren group. Diastolic blood pressure significantly decreased at 24 weeks (−6 mm Hg, p = 0.009) only in the amlodipine group. Although the estimated glomerular filtration rates did not significantly change in either group, the logarithm of urinary albumin excretion significantly decreased at 24 weeks only in the aliskiren group (−0.60, p < 0.001). The 24-week changes in the urinary albumin excretion significantly correlated with the changes in the plasma renin activity in the aliskiren group (r = 0.51, p = 0.008). Conclusion: Aliskiren monotherapy did not show any superiority to amlodipine monotherapy on VFA, estimated glomerular filtration rates, or urinary albumin excretion in obese or type 2 diabetic hypertensive patients.
- 20 October 2023
- Published by S. Karger AG in Kidney and Blood Pressure Research
- Vol. 48 (1) , 688-700
Open AccessEffects of Aliskiren Monotherapy versus Amlodipine Monotherapy in Hypertensive Patients with Obesity or Type 2 Diabetes Mellitus
Introduction: Renin-angiotensin system inhibitors have been reported to exert protective effects against organ damage and failure; however, the impact of the direct renin inhibitor as monotherapy has not been assessed. Here, we investigated the effects of 24-week monotherapy with aliskiren compared to amlodipine in hypertensive patients with type 2 diabetes or obesity. Methods: In this randomized intervention study, 62 adult hypertensive patients with visceral obesity (defined as a body mass index [BMI] greater than 25 kg/m2 and a visceral adipose tissue area [VFA] greater than 100 cm2) or type 2 diabetes mellitus (age 57 ± 13, 65% men, BMI 28.8 ± 4.8 kg/m2, VFA 134.8 ± 47.0 cm2, blood pressure 141 ± 16/86 ± 13 mm Hg) were randomized to receive 24-week treatment with aliskiren (max. 300 mg) or amlodipine (max. 10 mg). The primary outcome was the change in VFA at 24 weeks post-treatment. Results: Change in VFA did not differ significantly from baseline in either group. Systolic blood pressure significantly decreased at 12 weeks (−10 mm Hg, p = 0.001) and 24 weeks (−10 mm Hg, p = 0.001) in the amlodipine group and at 24 weeks (−11 mm Hg, p = 0.001) in the aliskiren group. Diastolic blood pressure significantly decreased at 24 weeks (−6 mm Hg, p = 0.009) only in the amlodipine group. Although the estimated glomerular filtration rates did not significantly change in either group, the logarithm of urinary albumin excretion significantly decreased at 24 weeks only in the aliskiren group (−0.60, p < 0.001). The 24-week changes in the urinary albumin excretion significantly correlated with the changes in the plasma renin activity in the aliskiren group (r = 0.51, p = 0.008). Conclusion: Aliskiren monotherapy did not show any superiority to amlodipine monotherapy on VFA, estimated glomerular filtration rates, or urinary albumin excretion in obese or type 2 diabetic hypertensive patients.
- Open Access
- 27 July 2021
- Published by Wiley in International Journal of Endocrinology
- Vol. 2021, 1-9
Immunohistochemistry for (Pro)renin Receptor in Humans
The (pro)renin receptor is a multifunctional protein with roles in angiotensin-II-dependent and -independent intracellular cell signaling and roles as an intracellular accessory protein for the vacuolar H+-ATPase, including hormone secretion. While (pro)renin receptor mRNA is widely expressed in various human tissues, localization of (pro)renin receptor protein expression has not yet been systemically determined. Therefore, this study localized (pro)renin receptor protein expression in human organs. Systemic immunohistochemical examination of (pro)renin receptor expression was performed in whole body organs of autopsy cases. (Pro)renin receptor immunostaining was observed in the cytoplasm of cells in almost all human organs. It was observed in thyroid follicular epithelial cells, hepatic cells, pancreatic duct epithelial cells, zona glomerulosa and zona reticularis of the cortex and medulla of the adrenal gland, proximal and distal tubules and collecting ducts of the kidney, cardiomyocytes, and skeletal muscle cells. In the brain, (pro)renin receptor staining was detected in neurons throughout all areas, especially in the medulla oblongata, paraventricular nucleus and supraoptic nucleus of the hypothalamus, cerebrum, granular layer of the hippocampus, Purkinje cell layer of the cerebellum, and the pituitary anterior and posterior lobes. In the anterior lobe of the pituitary gland, all types of anterior pituitary hormone-positive cells showed double staining with (pro)renin receptor. These data showed that (pro)renin receptor protein was expressed in almost all organs of the human body. Its expression pattern was not uniform, and cell-specific expression pattern was observed, supporting the notion that (pro)renin receptor plays numerous physiological roles in each human organ.
- 27 July 2021
- Published by Wiley in International Journal of Endocrinology
- Vol. 2021, 1-9
Open AccessImmunohistochemistry for (Pro)renin Receptor in Humans
The (pro)renin receptor is a multifunctional protein with roles in angiotensin-II-dependent and -independent intracellular cell signaling and roles as an intracellular accessory protein for the vacuolar H+-ATPase, including hormone secretion. While (pro)renin receptor mRNA is widely expressed in various human tissues, localization of (pro)renin receptor protein expression has not yet been systemically determined. Therefore, this study localized (pro)renin receptor protein expression in human organs. Systemic immunohistochemical examination of (pro)renin receptor expression was performed in whole body organs of autopsy cases. (Pro)renin receptor immunostaining was observed in the cytoplasm of cells in almost all human organs. It was observed in thyroid follicular epithelial cells, hepatic cells, pancreatic duct epithelial cells, zona glomerulosa and zona reticularis of the cortex and medulla of the adrenal gland, proximal and distal tubules and collecting ducts of the kidney, cardiomyocytes, and skeletal muscle cells. In the brain, (pro)renin receptor staining was detected in neurons throughout all areas, especially in the medulla oblongata, paraventricular nucleus and supraoptic nucleus of the hypothalamus, cerebrum, granular layer of the hippocampus, Purkinje cell layer of the cerebellum, and the pituitary anterior and posterior lobes. In the anterior lobe of the pituitary gland, all types of anterior pituitary hormone-positive cells showed double staining with (pro)renin receptor. These data showed that (pro)renin receptor protein was expressed in almost all organs of the human body. Its expression pattern was not uniform, and cell-specific expression pattern was observed, supporting the notion that (pro)renin receptor plays numerous physiological roles in each human organ.
- Open Access
- 1 June 2021
- Published by Bioscientifica in Endocrine Connections
- Vol. 10 (6) , 578-587
Clinical impacts of endothelium-dependent flow-mediated vasodilation assessment on primary aldosteronism
Objective: Primary aldosteronism (PA) is divided into two major subtypes, aldosterone-producing adenoma (APA) and bilateral idiopathic hyperplasia (IHA) and is associated with a higher risk of cardiovascular events. However, the nature of vascular function in PA patients remains to be determined. The aim of this study was to determine the vascular function and investigate the implications of vascular function assessments in the patients. Methods: Flow-mediated dilation (FMD), as an index of endothelial function, and cardio-ankle vascular index (CAVI), as an index of arterial stiffness, were retrospectively compared between 42 patients with APA, 37 patients with IHA, and 42 patients with essential hypertension (EH). These values were also compared with background factors, KCNJ5 mutation and clinical outcome in terms of blood pressure reduction after adrenalectomy in the APA group. Results: FMD was significantly lower in the APA group (4.8 ± 2.1%) and IHA group (4.1 ± 1.9%) than in the EH group (5.7 ± 2.1%). CAVI did not differ significantly among groups. Although no significant correlations were seen between FMD and background factors in the IHA group, FMD correlated negatively with BMI and plasma aldosterone concentration in the APA group (rs = −0.313, rs = −0.342, respectively). KCNJ5 mutational status was not associated with FMD value. High FMD was associated with blood pressure normalization after adrenalectomy in the APA group. Conclusions: Patients with PA displayed impaired endothelial function. Complete clinical success after adrenalectomy was associated with preserved endothelial function. This study provides a better understanding of FMD assessment in patients with PA.
- 1 June 2021
- Published by Bioscientifica in Endocrine Connections
- Vol. 10 (6) , 578-587
Open AccessClinical impacts of endothelium-dependent flow-mediated vasodilation assessment on primary aldosteronism
Objective: Primary aldosteronism (PA) is divided into two major subtypes, aldosterone-producing adenoma (APA) and bilateral idiopathic hyperplasia (IHA) and is associated with a higher risk of cardiovascular events. However, the nature of vascular function in PA patients remains to be determined. The aim of this study was to determine the vascular function and investigate the implications of vascular function assessments in the patients. Methods: Flow-mediated dilation (FMD), as an index of endothelial function, and cardio-ankle vascular index (CAVI), as an index of arterial stiffness, were retrospectively compared between 42 patients with APA, 37 patients with IHA, and 42 patients with essential hypertension (EH). These values were also compared with background factors, KCNJ5 mutation and clinical outcome in terms of blood pressure reduction after adrenalectomy in the APA group. Results: FMD was significantly lower in the APA group (4.8 ± 2.1%) and IHA group (4.1 ± 1.9%) than in the EH group (5.7 ± 2.1%). CAVI did not differ significantly among groups. Although no significant correlations were seen between FMD and background factors in the IHA group, FMD correlated negatively with BMI and plasma aldosterone concentration in the APA group (rs = −0.313, rs = −0.342, respectively). KCNJ5 mutational status was not associated with FMD value. High FMD was associated with blood pressure normalization after adrenalectomy in the APA group. Conclusions: Patients with PA displayed impaired endothelial function. Complete clinical success after adrenalectomy was associated with preserved endothelial function. This study provides a better understanding of FMD assessment in patients with PA.
- Open Access
- 1 April 2021
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 39 (Supplement) , e350
ASSOCIATION BETWEEN CARDIAC (PRO)RENIN RECEPTOR EXPRESSION AND MYOCARDIAL HYPERTROPHY IN HUMAN
Objective: The (pro)renin receptor [(P)RR] is expressed in vital organs throughout the body, with the highest expression level in the heart, and is thought to regulate the tissue renin-angiotensin system (RAS) through the non-proteolytic activation of prorenin. (P)RR is cleaved by processing enzymes to generate soluble (s)(P)RR, which is secreted into the extracellular space, and blood concentration of s(P)RR is considered to reflect the expression level of tissue RAS. Although it has been suggested that increased expression of (P)RR may be involved in cardiac pathophysiology in experimental studies, the significance of (P)RR expression in human heart remains unclear. Therefore, in the present studies, we investigated association between cardiac (P)RR expression and myocardial hypertrophy in human. Design and method: Study (1): We measured serum s(P)RR concentration and assessed the relationships between serum s(P)RR level and background factors including left ventricular mass index (LVMI) in 135 patients (57 males) of our department. Study (2): We performed immunostaining for (P)RR and atrial natriuretic peptide (ANP) and α-skeletal actin (SKA), markers for myocardial hypertrophy, in left ventricle specimens obtained from 13 autopsy cases. The expression level of (P)RR, ANP, or SKA and cardiomyocyte area were analyzed using an image processing software (ImageJ) and expression level of (P)RR was compared with cardiomyocyte area and expression level of ANP or SKA. Results: Study (1): The patients’ age was 57 (44–67) y.o., serum s(P)RR concentration was 22.8 (21.1–27.7) ng/ml, eGFR was 74.4 (59.4–91.2) ml/min/1.73 m2, and LVMI was 79 (66–90) g/ m2. Serum s(P)RR level was significantly positively correlated with LVMI (β = 0.238, p < 0.01) independent of other related factors. Study (2): (P)RR immunostaining was observed in cytoplasm of cardiomyocytes. The expression level of (P)RR was significantly positively correlated with cardiomyocyte area (ρ = 0.386, p < 0.001) and expression level of ANP (ρ = 0.782, p < 0.001) or SKA (ρ = 0.373, p < 0.001). Conclusions: These data suggested that cardiac (P)RR expression may be associated with myocardial hypertrophy in human. Further studies are needed to determine the underlying mechanism of this association.
- 1 April 2021
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 39 (Supplement) , e350
Open AccessASSOCIATION BETWEEN CARDIAC (PRO)RENIN RECEPTOR EXPRESSION AND MYOCARDIAL HYPERTROPHY IN HUMAN
Objective: The (pro)renin receptor [(P)RR] is expressed in vital organs throughout the body, with the highest expression level in the heart, and is thought to regulate the tissue renin-angiotensin system (RAS) through the non-proteolytic activation of prorenin. (P)RR is cleaved by processing enzymes to generate soluble (s)(P)RR, which is secreted into the extracellular space, and blood concentration of s(P)RR is considered to reflect the expression level of tissue RAS. Although it has been suggested that increased expression of (P)RR may be involved in cardiac pathophysiology in experimental studies, the significance of (P)RR expression in human heart remains unclear. Therefore, in the present studies, we investigated association between cardiac (P)RR expression and myocardial hypertrophy in human. Design and method: Study (1): We measured serum s(P)RR concentration and assessed the relationships between serum s(P)RR level and background factors including left ventricular mass index (LVMI) in 135 patients (57 males) of our department. Study (2): We performed immunostaining for (P)RR and atrial natriuretic peptide (ANP) and α-skeletal actin (SKA), markers for myocardial hypertrophy, in left ventricle specimens obtained from 13 autopsy cases. The expression level of (P)RR, ANP, or SKA and cardiomyocyte area were analyzed using an image processing software (ImageJ) and expression level of (P)RR was compared with cardiomyocyte area and expression level of ANP or SKA. Results: Study (1): The patients’ age was 57 (44–67) y.o., serum s(P)RR concentration was 22.8 (21.1–27.7) ng/ml, eGFR was 74.4 (59.4–91.2) ml/min/1.73 m2, and LVMI was 79 (66–90) g/ m2. Serum s(P)RR level was significantly positively correlated with LVMI (β = 0.238, p < 0.01) independent of other related factors. Study (2): (P)RR immunostaining was observed in cytoplasm of cardiomyocytes. The expression level of (P)RR was significantly positively correlated with cardiomyocyte area (ρ = 0.386, p < 0.001) and expression level of ANP (ρ = 0.782, p < 0.001) or SKA (ρ = 0.373, p < 0.001). Conclusions: These data suggested that cardiac (P)RR expression may be associated with myocardial hypertrophy in human. Further studies are needed to determine the underlying mechanism of this association.